跳至主要内容
临床试验/NCT02080494
NCT02080494Unknown不适用

Tranexamic Acid in Orthopaedic Trauma Surgery

University of Tennessee1 个研究点 分布在 1 个国家目标入组 101 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
101
试验地点
1
主要终点
hemoglobin value

研究概览

简要总结

Tranexamic acid is an antifibrinolytic drug that has been used to decrease post-operative blood loss. This study is a prospective, randomized controlled trial investigating the use of tranexamic acid in fracture surgery around the hip and knee, in which significant blood loss (>300mL) is expected.

The hypothesis of this study is that tranexamic acid will be associated with a decrease in post-operative blood loss, as well as a decreased need for allogenic blood transfusion, in patients who have fracture surgery around the hip and knee.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with isolated fractures of the pelvic ring, acetabulum, femur or tibia that will require open reduction and internal fixation
  • Expected blood loss is greater than 300 mL
  • Skeletal maturity

排除标准

  • Pregnant or breastfeeding
  • Patients taking oral contraceptives
  • Contraindication to venous thromboembolic event (VTE) prophylaxis (intracranial, intrathoracic, intra-abdominal bleeding or spine fractures)
  • Patients requiring operative intervention for other injuries (orthopaedic or non-orthopaedic)
  • Known hypercoagulable state including history of prescribed anti-coagulation (warfarin, plavix, low molecular weight heparin)
  • Renal Insufficiency (creatinine greater than 1.5mg/dL)
  • Open fractures

研究组 & 干预措施

Tranexamic Acid

Experimental

15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose

干预措施: Tranexamic Acid (Drug)

结局指标

主要结局

hemoglobin value

时间窗: through postoperative day four

次要结局

  • hematocrit value(through postoperative day four)
  • number of units of allogenic blood transfused(through postoperative day four)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验